We are live on ! Find out more
5VM

5AM Venture Management Portfolio holdings

AUM $360M
1-Year Est. Return 345.76%
This Fund
S&P 500
This Quarter Est. Return
-7.65%
1 Year Est. Return
+345.76%
3 Year Est. Return
+491.51%
5 Year Est. Return
+330.26%
10 Year Est. Return
–
AUM
$348M
AUM Growth
-$53.9M
Cap. Flow
+$6.12M
Cap. Flow %
1.76%
Top 10 Hldgs %
74.9%
Holding
26
New
2
Increased
2
Reduced
4
Closed
–

Top Buys

Rank Stock Value
1
DNTH icon
Dianthus Therapeutics
DNTH
+$18.5M
2
TYRA icon
Tyra Biosciences
TYRA
+$6.1M
3
GHRS icon
GH Research
GHRS
+$2.92M
4
VRDN icon
Viridian Therapeutics
VRDN
+$2.48M

Top Sells

Rank Stock Value
1
ELVN icon
Enliven Therapeutics
ELVN
+$10.7M
2
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$8.24M
3
IRON icon
Disc Medicine
IRON
+$2.5M
4
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$2.44M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CDTX
26
DELISTED
Cidara Therapeutics
CDTX
$1.07M 0.31%
56,726
– –
1
2

Similar funds

LSC
Logan Stone Capital Chicago, Illinois $360M AUM 9.71% 1-Year Est. Return
WIP
WealthCare Investment Partners Portsmouth, Rhode Island $360M AUM 19.98% 1-Year Est. Return
RA
RR Advisors Dallas, Texas $360M AUM 28.52% 1-Year Est. Return
SWM
SK Wealth Management Providence, Rhode Island $360M AUM 14.81% 1-Year Est. Return
NC
Naman Capital Sao Paulo, Brazil $360M AUM 27.43% 1-Year Est. Return
MCM
Monimus Capital Management Woodbridge, New Jersey $361M AUM 21.17% 1-Year Est. Return
KLWA
Kelly Lawrence W & Associates Pasadens, California $360M AUM 16.9% 1-Year Est. Return
PWC
PYA Waltman Capital Knoxville, Tennessee $361M AUM 9.49% 1-Year Est. Return

5AM Venture Management's Q3 2023 Portfolio in Review

As of Q3 2023, 5AM Venture Management held 26 positions worth $348M, down 13% from $401M the previous quarter. Its ten largest holdings account for 75% of the portfolio.

5AM Venture Management's Q3 2023 filing shows 2 new, 2 increased and 4 reduced positions. Its largest new stake was Dianthus Therapeutics: 1,472,264 shares worth $20.1M. The largest sale was Enliven Therapeutics, an estimated $10.7M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • 5AM Venture Management's largest Q3 2023 buy was Dianthus Therapeutics: 1,472,264 shares worth $20.1M.
  • 5AM Venture Management added most to GH Research in Q3 2023, an estimated $2.92M increase.
  • 5AM Venture Management's biggest Q3 2023 reduction was Enliven Therapeutics, cutting an estimated $10.7M.
  • 5AM Venture Management's ten largest holdings make up 75% of its $348M portfolio in Q3 2023.
  • 5AM Venture Management opened 2 new positions and closed 0 in Q3 2023.
  • 5AM Venture Management's portfolio value fell 13% quarter-over-quarter to $348M.

Based on 5AM Venture Management's 13F filing for Q3 2023, filed 14 Nov 2023.